UC’s Eric Vick receives major grants to advance research into combination therapy for leukemia

The University of Cincinnati Cancer Center’s Eric Vick, MD, PhD, has been awarded a nearly $215,000 Career Development Award from the Leukemia and Lymphoma Society (LLS) and a $50,000 American Society of Clinical Oncology (ASCO) Young Investigator Award to continue research into a combination therapy treatment for acute myeloid leukemia (AML).

AD/PD 2024: exploring cutting-edge therapies for ALS – Pharmaceutical Technology

Share this article The ALS treatment landscape includes therapies with different mechanisms, but they are not curative, prompting the need for disease-modifying therapies. Credit: Shutterstock/Juan

March 8, 2024

Acesion wins €45m in Series B funding to develop atrial fibrillation therapy – Pharmaceutical Technology

AP31969 is an oral SK ion channel inhibitor that is being developed as a maintenance treatment to prevent the recurrence of atrial fibrillation. Image Credit:

September 26, 2023

Coronary arterial inflammation linked to high cardiac event risk even without CAD

Researchers in The Lancet highlight coronary arterial inflammation’s role in increasing major adverse cardiac events and cardiovascular deaths, irrespective of coronary artery disease presence.

June 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.